Common Drug Review *

Submission Status

Product:	Brilinta
Generic Name:	ticagrelor
Manufacturer:	AstraZeneca Canada Inc
Indication:	Prevention of thrombotic events in Acute Coronary Syndromes
Submission Type:	Initial
Date Submission Received:	2011-Jun-01
Date NOC Issued:	2011-May-30
Targeted CDEC Meeting:	2011-Oct-19
Priority Review Granted:	Granted

	Phase	Target Time (Business Days)	Target Date **	Actual CDR Date	Comments
1	Submission deemed complete	5	2011-Jun-08	2011-Jun-08	- Priority review granted: 2011-Jul-18
2	Patient group input submission received				- Call for patient input posted on 2011-Jun-01 - Patient input deadline 2011-Jun-22 - Patient group input submissions received
3	CADTH Reviewers' Reports sent to Manufacturer	45	2011-Aug-24	2011-Aug-24	
4	Comments from Manufacturer on Reviewers' Reports Received by CADTH	7	2011-Sep-02	2011-Sep-02	- Additional information received. CDEC date to be determined based on review of information.
5	CDEC Meeting		2011-Oct-19	2011-Nov-16	- New due date for CDEC meeting to be determined based on review of information (see above). - New targeted date: 2011-Nov-16
6	CDEC Recommendation *** Sent to Drug Plans, FWG and Manufacturer	5 to 7	2011-Oct-26	2011-Nov-25	- New targeted date: 2011-Nov-25
7	Embargo Period **** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation	10	2011-Nov-09	2011-Dec-09	- New targeted date: 2011-Dec-09
8 (a)	Final Recommendation sent to Drug Plans, FWG, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5	2011-Nov-16	2011-Dec-16	- New targeted date: 2011-Dec-16 - Notice of Final Recommendation issued
	OR				
8 (b)	Clarification and Final Recommendation sent to Drug Plans, FWG, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
8 (c)	Placed on CDEC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
9	Final Recommendation sent to Drug Plans, FWG, and Manufacturer	5			

***** Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The Formulary review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CDEC meeting schedule, which is posted on www.cadth.ca.

*** The Procedure for Common Drug Review, section 8.3.3a, states "…the CDEC recommendation will be sent to the Manufacturer, FWG and to the drug plans within five (5) to seven (7) business days following the CDEC meeting…". The original target date is based on five (5) business days.

******** The Recommendation is held in confidence and not acted upon until after CADTH has issued the notice of Final Recommendation.

This submission status report reflects updates as of Thursday noon.